News & Events

Phoenix Data Systems Finalist in Data Driven Innovation Award

Company to Show the Latest in eClinical Data Solutions at SCDM 2008

King of Prussia , September 19, 2008 – Evidence that partnership is the best solution for success, Phoenix Data Systems (PDS), a subsidiary of Bio-Imaging Technologies (NASDAQ: BITI) and global provider of clinical data services including electronic data capture (EDC) and comprehensive eClinical data solutions, has been honored as a Data Driven Innovation Award finalist with its partner, Kyowa Pharmaceuticals, Inc. Along with this recognition, PDS is flexing its muscles as participant, presenter and silver sponsor at the Society of Clinical Data Management (SCDM) 14th Annual Conference at the Hyatt Regency Dallas, September 21-24 (booth #106/08).

Phoenix Data Systems is one of three finalists in the 2008 Data Driven Innovation Award, for its “Complex and robust data cleaning edit check system (Smart Forms for Smarter Trials)”. The award recognizes an outstanding vendor/sponsor relationship that developed a new technology based product or service to innovatively address the sponsor's study needs from a clinical data management perspective. The competition is open to any partnering organizations in the clinical data management industry, of any size, operating anywhere in the world. Winners will be announced during the Monday night Data Driven Innovation Award Reception on Monday, September 22, being held at Texas Stadium.

PDS at SCDM 2008
A silver sponsor of the conference, PDS delivers full service EDC, a unique combination of electronic data capture, interactive voice response, reporting, and data management services that give clinical data managers improved control to run well-managed studies. PDS assists its pharmaceutical, biotechnology, medical device and contract research organization clients with streamlining the clinical research process by providing early visibility to reliable clinical research data. Phoenix Data’s solutions have been proven in 600+ trials (September 2008), including pivotal trials for new drug application submissions to the FDA. PDS is growing rapidly and generated $12 million of revenue and an operating profit in 2007.

“With costs exceeding over$800 million dollars to develop a new drug, new solutions are needed to drive down costs for today’s pharmaceutical and biotechnology companies, as well as for consumers,” said Stephen Boccardo, Vice President, Sales of Phoenix Data Systems. “Phoenix Data Systems is at the forefront of EDC implementation for today’s businesses, helping to increase efficiency in drug development, save valuable staff time and improve bottom line results.”

Highlighting the expertise of the company and its staff, Jennifer Price, CCDM, Senior Director, Clinical Solutions of PDS will be presenting a session on “Using Metrics to Improve Clinical Trials using EDC” on Tuesday, September 23, 2008 from 10:30 a.m. to 12:00 p.m. The presentation will aim to give the participants ideas and solutions as to how applying the right metrics at the right time can help a project run smoothly and efficiently.

About Phoenix Data Systems
Phoenix Data Systems (PDS), a subsidiary of Bio-Imaging Technologies, is a global provider of clinical data services including electronic data capture (EDC) and comprehensive eClinical data solutions. PDS offers Full Service EDC (a unique combination of EDC, interactive voice response, reporting, and data management services) delivering value and efficiency while supporting all phases of clinical drug development. PDS has conducted 600+ trials (September 2008). Additional information about Phoenix Data Systems is available at www.phoenixdatasystems.net.

Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its Core Labs in Newtown, PA, and Leiden, The Netherlands, along with business offices in the United States, The Netherlands, Germany and France. Phoenix Data Systems, Inc., a subsidiary of Bio-Imaging Technologies, is a leading global clinical data services provider of electronic data capture (EDC) services and a comprehensive array of broadly interoperable eClinical data solutions to the pharmaceutical and biotechnology industries. Phoenix Data Systems delivers full service EDC, a unique combination of electronic data capture, interactive voice response, reporting, and data management solutions. Through its CapMed Personal Health Management Suite, Bio-Imaging provides its Personal HealthKey™ technology, the Personal Health Record (PHR) software, and CapMed Patient Portal allowing patients to better monitor and manage their health care information. Additional information about Bio-Imaging is available at www.bioimaging.com.

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forwardlooking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent form 10-Q.

Contact:

Bio-Imaging Technologies, Inc.

Jim Dorsey, VP – Marketing
Tel: 267-757-3040

Porter, LeVay & Rose, Inc.
Linda Decker, VP - Investor Relations
Tel: (212) 564-4700